This week on the podcast, John has a very awe-inspiring conversation with Stacy Blain, co-founder and Chief Scientific Officer at Concarlo Therapeutics. The team of scientists at Concarlo is developing new medications that use p27, a natural inhibitor, to stop cancer cells from multiplying in drug-resistant patients.
A discovery made in a university setting led Stacy Blain to pursue a further investigation and drug development on her own, for which she had to navigate an extensive process of entrepreneurship, assembling her own team, and finding funds to change the way cancer is treated. She shares the journey it took her to get Concarlo to where it currently is and explains the work they are doing with p27, in addition to targeted therapy, to bring cancer patients a treatment that is less toxic and seeks to avoid remission, mutations, or ultimately, drug resistance.